Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera (NTRA) reported an insider equity change by its SEC. and Chief Legal Officer. On 10/20/2025, 856 shares of common stock were acquired through the vesting of RSUs, and on 10/21/2025, 464 shares were sold at $187.95 to cover tax withholding and remittance obligations pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following these transactions, the officer directly owned 203,692 shares. Each RSU represents a right to receive one share. The RSUs vest over four years: 25% vested on January 20, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction on a Form 4. An officer serving as President, Clinical Diagnostics sold 292 shares of common stock at $187.95 on 10/21/2025. The filing states the sale was made to satisfy tax withholding obligations related to RSU vesting and was conducted under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Following the transaction, the officer beneficially owned 117,267 shares, held directly.
Natera, Inc. (NTRA) disclosed a Form 4 for its President and Chief Business Officer reporting a sale of 339 shares of common stock on 10/21/2025 at $187.95 per share (code S). The filing states the shares were sold to satisfy tax withholding and remittance obligations tied to vesting RSUs and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the transaction, the officer directly owned 152,408 shares.
Natera (NTRA) reported an insider transaction by its CEO and President, who is also a director. On 10/20/2025, 3,386 Restricted Stock Units vested and were converted to common stock (code M). On 10/21/2025, 1,603 shares were sold at $187.95 per share (code S) to satisfy tax withholding, under a Rule 10b5-1(c) instruction tied to a January 28, 2022 grant. Following these transactions, the reporting person directly beneficially owns 155,855 shares.
The RSU award vests over four years: 25% on January 20, 2023, with the remainder in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction by its chief financial officer. On Oct 20, 2025, 1,522 RSUs vested and were settled into common stock. On Oct 21, 2025, 602 shares were sold at $187.95 to satisfy tax withholding, pursuant to a written instruction intended to meet Rule 10b5-1(c) conditions. Following these transactions, the officer held 70,109 shares directly.
The RSUs relate to a grant dated Jan 28, 2022 and vest over four years: 25% vested on Jan 20, 2023, with the balance vesting in 12 equal quarterly installments thereafter.
Natera, Inc. filed a Form S-8 to register 3,600,000 additional shares of common stock under its Amended and Restated 2015 Equity Incentive Plan. The filing uses General Instruction E to add shares to a previously registered plan and incorporates prior S-8 filings by reference.
Natera is listed as a large accelerated filer. The registration includes standard indemnification disclosures for directors and officers and appends required exhibits, including a legal opinion and auditor consent.
Natera (NTRA) co‑founder and director reported open‑market sales of common stock made under Rule 10b5‑1 trading plans. On 10/15/2025, sales of 153, 1,506, 988, and 423 shares executed at weighted average prices of $172.9918, $175.1097, $175.8967, and $176.6252. Direct holdings were 236,112 shares after these transactions.
On 10/17/2025, trusts sold 475, 275, 413, and 337 shares at weighted average prices of $178.6601, $179.3511, $178.5818, and $179.2912. Indirect holdings were 28,032 shares in Caraluna 1 Trust and 28,032 shares in Caraluna 2 Trust; the reporting person disclaims beneficial ownership of trust-held shares.
Insider filing summary: Natera, Inc. director and Secretary & Chief Legal Officer Daniel Rabinowitz had 2,500 restricted stock units (RSUs) vest on 09/29/2025, each representing one share. Those RSUs converted into 2,500 shares of common stock. On 09/30/2025 the reporting person sold 1,364 shares at $162.0528 per share to satisfy tax withholding obligations tied to the RSU vesting, leaving the reporting person with 203,300 shares beneficially owned after the transactions. The sale was made pursuant to written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions.
Michael Brophy, Chief Financial Officer of Natera, Inc. (NTRA), reported vesting and a subsequent sale of shares tied to restricted stock units. On 09/29/2025 6,250 RSUs vested from a 25,000-share grant originally issued on 01/22/2021, where each RSU converts to one share. The reporting shows an immediate beneficial ownership increase to 71,680 shares, followed by a sale on 09/30/2025 of 2,491 shares at $162.0528 per share to satisfy tax withholding, leaving 69,189 shares beneficially owned. The sale was carried out under a written instruction intended to meet Rule 10b5-1(c) conditions. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Form 144 filing for Natera, Inc. (NTRA) reporting a proposed sale of 14,083 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $2,253,232.54. The shares represent restricted stock acquired from the issuer on 09/28/2025 and the filer indicates the approximate date of sale as 10/01/2025 on NASDAQ. The filing lists five prior sales by the same person during the past three months totaling 23,943 shares with gross proceeds shown for each sale. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.